162 related articles for article (PubMed ID: 8910583)
1. Topoisomerase II.etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes.
Burden DA; Kingma PS; Froelich-Ammon SJ; Bjornsti MA; Patchan MW; Thompson RB; Osheroff N
J Biol Chem; 1996 Nov; 271(46):29238-44. PubMed ID: 8910583
[TBL] [Abstract][Full Text] [Related]
2. Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Robinson MJ; Corbett AH; Osheroff N
Biochemistry; 1993 Apr; 32(14):3638-43. PubMed ID: 8385484
[TBL] [Abstract][Full Text] [Related]
3. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
4. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Kingma PS; Burden DA; Osheroff N
Biochemistry; 1999 Mar; 38(12):3457-61. PubMed ID: 10090731
[TBL] [Abstract][Full Text] [Related]
5. Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.
Robinson MJ; Osheroff N
Biochemistry; 1991 Feb; 30(7):1807-13. PubMed ID: 1847075
[TBL] [Abstract][Full Text] [Related]
6. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide.
Osheroff N
Biochemistry; 1989 Jul; 28(15):6157-60. PubMed ID: 2551366
[TBL] [Abstract][Full Text] [Related]
7. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
DeVore RF; Corbett AH; Osheroff N
Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
[TBL] [Abstract][Full Text] [Related]
10. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage.
Robinson MJ; Martin BA; Gootz TD; McGuirk PR; Moynihan M; Sutcliffe JA; Osheroff N
J Biol Chem; 1991 Aug; 266(22):14585-92. PubMed ID: 1650363
[TBL] [Abstract][Full Text] [Related]
11. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
12. Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Corbett AH; Hong D; Osheroff N
J Biol Chem; 1993 Jul; 268(19):14394-8. PubMed ID: 8390992
[TBL] [Abstract][Full Text] [Related]
13. Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Infante Lara L; Fenner S; Ratcliffe S; Isidro-Llobet A; Hann M; Bax B; Osheroff N
Nucleic Acids Res; 2018 Mar; 46(5):2218-2233. PubMed ID: 29447373
[TBL] [Abstract][Full Text] [Related]
14. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
15. The geometry of DNA supercoils modulates topoisomerase-mediated DNA cleavage and enzyme response to anticancer drugs.
McClendon AK; Osheroff N
Biochemistry; 2006 Mar; 45(9):3040-50. PubMed ID: 16503659
[TBL] [Abstract][Full Text] [Related]
16. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
J Biol Chem; 1999 Dec; 274(50):35927-32. PubMed ID: 10585479
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.
Robinson MJ; Osheroff N
Biochemistry; 1990 Mar; 29(10):2511-5. PubMed ID: 2159323
[TBL] [Abstract][Full Text] [Related]
18. Interactions between the etoposide derivative F14512 and human type II topoisomerases: implications for the C4 spermine moiety in promoting enzyme-mediated DNA cleavage.
Gentry AC; Pitts SL; Jablonsky MJ; Bailly C; Graves DE; Osheroff N
Biochemistry; 2011 Apr; 50(15):3240-9. PubMed ID: 21413765
[TBL] [Abstract][Full Text] [Related]
19. In vitro evolution of preferred topoisomerase II DNA cleavage sites.
Burden DA; Osheroff N
J Biol Chem; 1999 Feb; 274(8):5227-35. PubMed ID: 9988773
[TBL] [Abstract][Full Text] [Related]
20. Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II.
Kuriappan JA; Osheroff N; De Vivo M
J Chem Inf Model; 2019 Sep; 59(9):4007-4017. PubMed ID: 31449404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
